Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 9/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30647434 | 1.00 | MKNK1 (0.53) | MKNK1PARP1SYKMKNK2STAT6 | |
| SCHEMBL30647326 | 0.87 | MKNK1 (0.47) | MKNK1PARP1SYKMKNK2STAT6 | |
| SCHEMBL21265791 | 0.87 | MKNK1 (0.47) | MKNK1PARP1SYKMKNK2STAT6 | |
| SCHEMBL21265490 | 0.86 | JAK2 (0.56) | MKNK1SYKSTAT6FLT3 | |
| SCHEMBL30647365 | 0.86 | JAK2 (0.56) | MKNK1SYKSTAT6FLT3 | |
| SCHEMBL21265792 | 0.85 | MKNK1 (0.62) | MKNK1SYKMKNK2STAT6CSF1R | |
| SCHEMBL30647390 | 0.85 | MKNK1 (0.62) | MKNK1SYKMKNK2STAT6CSF1R | |
| SCHEMBL21265437 | 0.85 | STAT6 (0.53) | MKNK1SYKMKNK2STAT6CSF1R | |
| SCHEMBL30647342 | 0.85 | STAT6 (0.53) | MKNK1SYKMKNK2STAT6CSF1R | |
| SCHEMBL21265532 | 0.84 | MKNK1 (0.59) | MKNK1SYKSTAT6CSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| CN-111566100-A | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019154177-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | CDK9, CDK19, CDK6 | MKNK1 390/4885PARP1 958/4885SYK 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.